40535-45-3

Usage

Common Uses

Building block in the synthesis of pharmaceuticals and agrochemicals

Chirality

Chiral molecule with a non-superimposable mirror image

Applications

Production of chiral drugs and intermediates

Role in Catalysis

Used as a ligand

Role in Organic Synthesis

Used as a reagent

Industry Applications

Wide range of applications in pharmaceutical and chemical industries

Importance

Important and versatile molecule in organic chemistry

Upstream product

• 6635-29-6 cyclopentane-1,2-dione dioxime 
• 10230-26-9 trans-1,2-dibromocyclopentane 
• 287-92-3 Cyclopentane 
• 1461-96-7 Cyclopentan-1,2-trans-dicarbonsaeure 
• 5057-99-8 trans-cyclopentane-1,2-diol 
• 142-29-0 cyclopentene 

Downstream Products

• 1417905-86-2 1,2-trans-diaminocyclopentane diiodoplatinum(II) 
• 786712-29-6 cis-N,N'-bis-(2,4,6-triisopropyl)phenylsulfonyl-1,2-diaminocyclopentane 
• 1193388-07-6 (1R*,2R*)-2-aminocyclopentylcarbamic acid tert-butyl ester 
• 1193388-07-6 tert-butyl rac-trans-(2-aminocyclopentyl)carbamate 

Relevant academic research and scientific papers

The synthesis and use in asymmetric epoxidation of metal salen complexes derived from enantiopure trans-cyclopentane- and cyclobutane-1,2-diamine

A complete synthesis of enantiopure trans-cyclopentane-1,2-diamine and trans-cyclobutane-1,2-diamine is described. These diamines have been used as components of novel chiral salen ligands whose chromium and manganese complexes were then evaluated as oxygen transfer agents in the asymmetric epoxidation of alkenes.

A method for the treatment of tumor cell proliferative diseases of platinum (II) compound

Disclosed are a platinum compound with the leaving group malonic derivative "2" position substituent containing a primary amino, a secondary amino, a tertiary amino, and a quaternary amino, as well as pharmaceutically acceptable salt, preparation method thereof, and pharmaceutical composition containing the compound. Also disclosed are uses of the compound for treating cell proliferative diseases, particularly cancers. The platinum compound of the present invention has the high water solubility and the low toxicity.

PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO

Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compou

PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF

Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

Synthesis of two stereoisomeric polydentate ligands, trans and cis cyclopentane-1,2-diaminotetraacetic acids, and complexation by 111In and 153Sm

Two polyaminocarboxylic acid chelating agents were synthesized. Complexation properties regarding 111In and 153Sm, two radionuclides suitable for applications in immunoscintigraphy and radioimmunotherapy were investigated. The synthesis of aminodiacetic acid derivatives 7a and 7b involved preliminary stereoselective synthesis of the corresponding amines, cis and trans cyclopentane-1,2-diamines. 111In labelling confirmed the complexation abilities of the two ligands. An additional comparative study to probe the relationship between ligand structure and metal complex was performed with 153Sm.